



NORRIS
MEDICINES LIMITED



Factory : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 13/02/2021

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

**Subject: Submission of Standalone Unaudited Financial Results in compliance
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,


Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter ended on 31st December, 2020.
- 2) Limited Review Report by Statutory Auditors on Standalone Unaudited Financial Results for the quarter ended on 31st December, 2020

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,
For Norris Medicines Limited


(Vinay Rana)
Company Secretary



Encl: As above



NORRIS

MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)
 Telephone : (02646) 223462, 227530
 Fax : (02646) 250126
 E-mail : contact@norrispharma.com
 Website : www.norrispharma.com
 CIN : L24230GJ1990PLC086581


STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2020

Sr. No.	Particulars	(Rs. in Lakhs)					
		Quarter Ended			Nine Months Ended		Year Ended
		31.12.2020 Unaudited	30.09.2020 Unaudited	31.12.2019 Unaudited	31.12.2020 Unaudited	31.12.2019 Unaudited	31.03.2020 Audited
i	Revenue from Operations	466.98	316.49	176.45	967.70	648.80	784.37
ii	Other Income	0.07	0.04	0.04	2.57	0.83	8.52
iii	Total Revenue (i+ii)	467.05	316.53	176.49	970.27	649.63	792.89
iv	Expenses						
	(a) Cost of Materials Consumed	271.21	281.74	97.85	556.93	342.29	516.30
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	40.39	-21.06	-15.73	108.98	16.32	-63.90
	(c) Employee Benefit Expenses	98.09	80.51	88.17	227.09	249.61	322.54
	(d) Finance Costs	19.93	27.74	15.49	58.78	52.36	88.23
	(e) Depreciation and Amortisation Expense	18.00	18.00	17.80	54.00	53.40	72.88
	(f) Other expenditure	43.64	58.88	44.83	143.24	164.73	224.94
	Total Expenses (iv)	491.26	445.81	248.41	1149.02	878.71	1160.99
v	Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)	-24.21	-129.28	-71.92	-178.75	-229.08	-368.10
vi	Exceptional items	0	0	0	0	0	0
vii	Profit/ (Loss) before extraordinary items and tax (v-vi)	-24.21	-129.28	-71.92	-178.75	-229.08	-368.10
viii	Extraordinary items	0	0	0	0	0	0
ix	Profit/ (Loss) before Tax (vii-viii)	-24.21	-129.28	-71.92	-178.75	-229.08	-368.10
x	Tax Expense						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-83.99
xi	Profit / Loss after Tax	-24.21	-129.28	-71.92	-178.75	-229.08	-284.11
xii	Other Comprehensive Income	0	0	0	0	0	0
	Total Comprehensive Income for the period	-24.21	-129.28	-71.92	-178.75	-229.08	-284.11
xiii	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
xiv	- Basic and diluted	-0.24	-1.29	-0.72	-1.79	-2.29	-2.84

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13.02.2021. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016..
- 3) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 4) There are no exceptional/extraordinary items during the quarter ended 31.12.2020.
- 5) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited


 Vimal D Shah
 Managing Director



Date: 13/02/2021
 Place: Ankleshwar



H.N. JADAV & CO.
CHARTERED ACCOUNTANTS

CA Harishchandra N. Jadav
B. Com, FCA, DISA (ICAI)
Mobile : 98241 25540
harishnjadav@yahoo.com
harishnjadav@gmail.com

C-24, GROUND FLOOR, SARDAR PATEL MUNICIPAL MARKET, SHAKTINATH, BHARUCH- 392 001.

Limited Review Report

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the Quarter ended **31st December, 2020**, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/CMDI/44/2019 dated March 29, 2019. This Statement, which is the responsibility of the Company's Management and has been Prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (**SRE**) **2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with IND AS i.e applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. CIR/CFD/CMDI/44/2019 dated March 29, 2019 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 13/02/2021

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat



For, H. N. JADAV & Co.
Chartered Accountants

CA HARISHCHANDRA JADAV
Proprietor
M. No. 040525
Firm Reg. No. 103801W
UDIN: 21040525AAAAV1623